Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Investment
Features
FeesSafety
Academy
More
Pluang+

Compare C3.ai Inc (AI) vs Amphastar Pharmaceuticals Inc (AMPH) Price & Performance

C3.ai Inc
Amphastar Pharmaceuticals Inc

Price performance

Price movement over the last 24 hours

Key statistics

C3.ai Inc vs Amphastar Pharmaceuticals Inc — how do they compare? C3.ai Inc trades at $8.87 (market cap $1.39B), while Amphastar Pharmaceuticals Inc trades at $18.77 (market cap $885.83M). The key difference: C3.ai Inc is the larger of the two by market cap. Which is the better fit depends on your goals.

AIAMPH
Market Cap
$1.39B$885.83M
Sector
TechnologyHealth
52-Week High
$29.16$30.81
52-Week Low
$7.76$16.87
Enterprise Value
$818.29M$1.28B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

C3.ai Inc

C3.ai trades at $8.93, down 1.43% with bearish technical signals. The company shows revenue growth to $389M in 2025 but continues significant losses with -$289M net income. Analyst sentiment is mixed with 21% buy ratings and consensus target of $10.20. Recent developments include board member Jim Hagemann Snabe's appointment as European Commission Special Envoy for Industrial AI.

While revenue growth presents opportunity, persistent losses and negative cash flow pose substantial risk. The stock faces headwinds from unprofitability despite beating some earnings estimates. Upside potential exists if the company can accelerate path to profitability amid growing enterprise AI adoption.

Amphastar Pharmaceuticals Inc

AMPH trades at $19.61, down 0.15% with a bearish technical outlook. The stock shows mixed fundamentals with a P/E of 11.81 and net margin of 11%, but recent earnings misses and declining 2026 profit projections raise concerns. Recent news includes a Zacks Strong Sell rating and a securities law investigation, while management focuses on transitioning to proprietary drugs for growth.

The outlook remains cautious with analyst consensus at Hold (66.7%) and a $20.40 price target offering limited upside. Key risks include earnings volatility, competitive pressures, and legal scrutiny. The stock presents moderate value but requires careful monitoring of execution on growth initiatives and upcoming Q2 earnings.

Returns comparison

Trailing returns across standard periods

About C3.ai Inc

C3.ai Inc is an enterprise artificial intelligence company. The company provides software-as-a-service applications that enable customers to rapidly develop, deploy, and operate large-scale Enterprise AI applications across any infrastructure. It provides solutions under three divisions namely, The C3 AI Suite, is a comprehensive application development and runtime environment that is designed to allow customers to rapidly design, develop, and deploy Enterprise AI applications of any type

Read more on AI

About Amphastar Pharmaceuticals Inc

Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.

Read more on AMPH